Biocon is looking to tap the global marketing clout of Sandoz by striking a deal to hand over distribution rights to its Humira (adalimumab) biosimilar in Japan.
Sandoz is continuing to further its global biosimilar ambitions, striking a distribution agreement in Japan with Biocon for the Indian firm’s adalimumab biosimilar, in one of Biocon’s first major deals since completing the integration of Viatris’s biosimilars business “in around 120 countries across advanced and emerging markets.”
“Viatris has completed marketing and promotion of the product as of 15 December but will continue to provide transition support...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
